Mutation of gyrA and parC in clinical isolates of Acinetobacter baumannii and its relationship with antimicrobial drugs resistance in Taiwan

Annals of Microbiology

Volumn 59, Issue 2, 2009, Pages 369-372

  Chien, Shang Tao ^a   Lin, Chun Hsiu ^a   Hsueh, Jui Chen ^a   Li, Pei Ling ^a   Hsu, Chao Hsun ^a   Chang, Shu Hui ^a   Chien, Hsin I ^a   Ben, Ren Jy ^a   Chang, Fu Hsin ^b   Hsu, Li Sung ^c  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b Asia Pacific Biotech Developing Inc   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii; Antibacterial drugs; GyrA; ParC

Indexed keywords

ACINETOBACTER BAUMANNII; NEGIBACTERIA;

EID: 77955490963     PISSN: 15904261     EISSN: 18692044     Source Type: Journal    
DOI: 10.1007/BF03178341     Document Type: Article

References (24)

1. Bergogne-Berezin E., Towner K.J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev., 9: 148-165.
2. Chau S.L., Chu Y.W., Houang E.T. (2004). Novel resistancenodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob. Agents Chemother., 48: 4054-4055.
3. Friedman S.M., Lu T., Drlica K. (2001). Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother., 45: 2378-2380.
4. Getchell-White S.I., Donowitz L.G., Groschel D.H. (1989). The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect. Control Hosp. Epidemiol., 10: 402-407.
5. Goldstein F.W., Acar J.F. (1995). Epidemiology of quinolone resistance: Europe and North and South America. Drugs, 49 Suppl. 2: 36-42.
6. Goswitz J.J., Willard K.E., Fasching C. E., Peterson L.R. (1992). Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob. Agents Chemother., 36: 1166-1169.
7. Heisig P., Schedletzky H., Falkenstein-Paul H. (1993). Mutations In the gyrA gene of a highly fluoroquinolone-resistant clinical Isolate of Escherichia coli. Antimicrob. Agents Chemother., 37: 696-701.
8. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. (1994). Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother., 38: 2014-2023.
9. Jacoby G. A. (2005). Mechanisms of resistance to quinolones. Clin. Infect. Dis., 41 Suppl. 2: S120-S126.
10. Jain R., Danziger L.H. (2004). Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother., 38: 1449-1459.
11. Jawad A., Heritage J., Snelling A.M., Gascoyne-Blnzi D.M., Hawkey P.M. (1996). Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J. Clin. Microbiol., 34: 2881-2887.
12. Koeleman J.G., Parlevliet G.A., Dijkshoorn L., Savelkoul P.H., Vandenbroucke-Grauls C.M. (1997). Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J. Hosp. Infect., 37: 113-123.
13. Kureishi A., Diver J.M., Beckthold B., Schollaardt T., Bryan L.E. (1994). Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob. Agents Chemother., 38: 1944-1952.
14. Lee J.K., Lee Y.S., Park Y.K., Kim B.S. (2005). Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol. Immunol., 49: 647-653.
15. Levine C., Hiasa H., Marians K.J. (1998). DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta, 1400: 29-43.
16. Ling T.K., Ying C.M., Lee C.C., Liu Z.K. (2005). Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong. Med. Princ. Pract., 14: 338-341.
17. Piddock L.J. (1999). Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs, 58 Suppl. 2: 11-18.
18. Scerpella E.G., Wanger A.R., Armitige L., Anderlini P., Ericsson C.D. (1995). Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations. Infect. Control Hosp. Epidemiol., 16: 92-97.
19. Vila J., Ruiz J., Marco F., Barcelo A., Goni P., Giralt E., Jimenez de Anta T. (1994). Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother., 38: 2477-2479.
20. Vila J., Ruiz J., Goni P., Marcos A., Jimenez de Anta T. (1995). Mutation In the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother., 39: 1201-1203.
21. Vila J., Ruiz J., Goni P., Jimenez de Anta T. (1997). Quinoloneresistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J. Antimicrob. Chemother., 39: 757-762.
22. Wang Y., Huang W.M., Taylor D.E. (1993). Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob. Agents Chemother., 37: 457-463.
23. Yamagishi J., Yoshida H., Yamayoshi M., Nakamura S. (1986). Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol. Gen. Genet., 204: 367-373.
24. Yoshida H., Kojima T., Yamagishi J., Nakamura S. (1988). Quinolone-reslstant mutations of the gyrA gene of Escherichia coli. Mol. Gen. Genet., 211: 1-7.